We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Dermata Therapeutics Inc (DRMA) USD0.0001

Sell:$1.35 Buy:$1.37 Change: $0.11 (8.94%)
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
Sell:$1.35
Buy:$1.37
Change: $0.11 (8.94%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
Sell:$1.35
Buy:$1.37
Change: $0.11 (8.94%)
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, DMT310, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 50 million patients. Its second product candidate utilizing its Spongilla technology is DMT410, its combination treatment. DMT410 is intended to consist of one treatment of its proprietary sponge powder followed by one topical application of botulinum toxin for delivery into the dermis.

Contact details

Address:
3525 Del Mar Heights Rd., #322
SAN DIEGO
92130
United States
Telephone:
+1 (858) 2230882
Website:
https://www.dermatarx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
DRMA
ISIN:
US2498454055
Market cap:
$2.73 million
Shares in issue:
2.04 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Gerald Proehl
    Chairman of the Board, President, Chief Executive Officer
  • Kyri Van Hoose
    Chief Financial Officer, Senior Vice President
  • Maria Bedoya Toro Munera
    Senior Vice President - Regulatory Affairs & Quality Assurance
  • Christopher Nardo
    Senior Vice President, Chief Development Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.